A Thiol-reactive 18F-labeling Agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and Synthesis of RGD Peptide-based Tracer for PET Imaging of Alpha V Beta 3 Integrin Expression

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2006 Jul 5

PMID 16818952

Citations 67

Authors

Weibo Cai

Xianzhong Zhang

Yun Wu

Xiaoyuan Chen

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The cell adhesion molecule integrin alpha v beta 3 plays a key role in tumor angiogenesis and metastasis. A series of 18F-labeled RGD peptides have been developed for PET of integrin expression based on primary amine-reactive prosthetic groups. In this study we introduced a new method of labeling RGD peptides through a thiol-reactive synthon, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide (18F-FBEM).

Methods: 18F-FBEM was synthesized by coupling N-succinimidyl 4-18F-fluorobenzoate (18F-SFB) with N-(2-aminoethyl)maleimide. After high-pressure liquid chromatography purification, it was allowed to react with thiolated RGD peptides, and the resulting tracers were subjected to receptor-binding assay, in vivo metabolic stability assessment, biodistribution, and microPET studies in murine xenograft models.

Results: Conjugation of monomeric and dimeric sulfhydryl-RGD peptides with 18F-FBEM was achieved in high yields (85% +/- 5% nondecay-corrected on the basis of 18F-FBEM). The radiochemical purity of the 18F-labeled peptides was >98% and the specific activity was 100 approximately 150 TBq/mmol. Noninvasive microPET and direct tissue sampling experiments demonstrated that both 18F-FBEM-SRGD (RGD monomer) and 18F-FBEM-SRGD2 (RGD dimer) had integrin-specific tumor uptake in subcutaneous U87MG glioma and orthotopic MDA-MB-435 breast cancer xenografts.

Conclusion: The new tracer 18F-FBEM-SRGD2 was synthesized with high specific activity via 18F-FBEM and the tracer exhibited high receptor-binding affinity, tumor-targeting efficacy, metabolic stability, as well as favorable in vivo pharmacokinetics. The new synthon 18F-FBEM developed in this study will also be useful for radiolabeling of other thiolated biomolecules.

Citing Articles

[Ga]Ga-LNC1007 versus 2-[F]FDG in the evaluation of patients with metastatic differentiated thyroid cancer: a head-to-head comparative study.

Chen Y, Zheng S, Zang J, Shao Z, Tu D, Liu Q Eur J Nucl Med Mol Imaging. 2024; 52(2):683-692.

PMID: 39404790 DOI: 10.1007/s00259-024-06930-4.

From molecules to medicine: thiol selective bioconjugation in synthesis of diagnostic and therapeutic radiopharmaceuticals.

Bibi I, Mushtaq S, Lee K, Park J, Kim J Theranostics. 2024; 14(6):2396-2426.

PMID: 38646656 PMC: 11024863. DOI: 10.7150/thno.95469.

Deoxyfluorination of phenols for chemoselective F-labeling of peptides.

Halder R, Ma G, Rickmeier J, McDaniel J, Petzold R, Neumann C Nat Protoc. 2023; 18(11):3614-3651.

PMID: 37853158 DOI: 10.1038/s41596-023-00890-z.

Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.

Failla M, Floresta G, Abbate V RSC Med Chem. 2023; 14(4):592-623.

PMID: 37122545 PMC: 10131587. DOI: 10.1039/d2md00397j.

Fluorine-18: Radiochemistry and Target-Specific PET Molecular Probes Design.

Wang Y, Lin Q, Shi H, Cheng D Front Chem. 2022; 10:884517.

PMID: 35844642 PMC: 9277085. DOI: 10.3389/fchem.2022.884517.

References

Visvikis D, Costa D, Bomanji J, Gacinovic S, Ell P . Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. Eur J Nucl Med. 2001; 28(9):1326-35. View

Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M . MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging. 2004; 31(8):1081-9. DOI: 10.1007/s00259-003-1452-2. View

Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman S, Jankun J . A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther. 2003; 2(1):19-28. View

Kumar C . Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003; 4(2):123-31. DOI: 10.2174/1389450033346830. View

Saito G, Swanson J, Lee K . Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev. 2003; 55(2):199-215. DOI: 10.1016/s0169-409x(02)00179-5. View

Hood J, Cheresh D . Role of integrins in cell invasion and migration. Nat Rev Cancer. 2003; 2(2):91-100. DOI: 10.1038/nrc727. View

Janssen M, Oyen W, Massuger L, Frielink C, Dijkgraaf I, Edwards D . Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2003; 17(6):641-6. DOI: 10.1089/108497802320970244. View

Haubner R, Wester H, Weber W, Schwaiger M . Radiotracer-based strategies to image angiogenesis. Q J Nucl Med. 2003; 47(3):189-99. View

Bogenrieder T, Herlyn M . Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003; 22(42):6524-36. DOI: 10.1038/sj.onc.1206757. View

10.

Toyokuni T, Walsh J, Dominguez A, Phelps M, Barrio J, Gambhir S . Synthesis of a new heterobifunctional linker, N-[4-(aminooxy)butyl]maleimide, for facile access to a thiol-reactive 18F-labeling agent. Bioconjug Chem. 2003; 14(6):1253-9. DOI: 10.1021/bc034107y. View

11.

Chen X, Park R, Tohme M, Shahinian A, Bading J, Conti P . MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004; 15(1):41-9. DOI: 10.1021/bc0300403. View

12.

Chen X, Park R, Shahinian A, Tohme M, Khankaldyyan V, Bozorgzadeh M . 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004; 31(2):179-89. DOI: 10.1016/j.nucmedbio.2003.10.002. View

13.

Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G . Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med. 2004; 45(5):892-902. View

14.

Schottelius M, Poethko T, Herz M, Reubi J, Kessler H, Schwaiger M . First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res. 2004; 10(11):3593-606. DOI: 10.1158/1078-0432.CCR-03-0359. View

15.

Cai W, Gambhir S, Chen X . Multimodality tumor imaging targeting integrin alphavbeta3. Biotechniques. 2010; 39(6 Suppl):S14-25. DOI: 10.2144/000112091. View

16.

Chen X, Tohme M, Park R, Hou Y, Bading J, Conti P . Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging. 2004; 3(2):96-104. DOI: 10.1162/15353500200404109. View

17.

Chen X, Liu S, Hou Y, Tohme M, Park R, Bading J . MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004; 6(5):350-9. DOI: 10.1016/j.mibio.2004.06.004. View

18.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I . Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med. 2004; 45(10):1776-83. View

19.

Kilbourn M, Dence C, Welch M, Mathias C . Fluorine-18 labeling of proteins. J Nucl Med. 1987; 28(4):462-70. View

20.

Shai Y, Kirk K, Channing M, Dunn B, Lesniak M, Eastman R . 18F-labeled insulin: a prosthetic group methodology for incorporation of a positron emitter into peptides and proteins. Biochemistry. 1989; 28(11):4801-6. PMC: 3425638. DOI: 10.1021/bi00437a042. View